Number of patients | 98 |
Age (median, range) | 58 (19–89) |
Sex | |
 M | 57 |
 F | 41 |
Onset | |
 Primary | 78 (80%) |
 Post-MDS/MPN | 10 (10%) |
 Post-therapy | 10 (10%) |
Blasts % (median, range) | 70 (20-95) |
WBC, (median, range) x 109/L | 7.9 (0.8–35) |
Hb, (median, range) x g/dL | 9.6 (4–15.5) |
PLT, (median, range) x 109/L | 50.5 (1.7–656) |
Karyotype | |
 Normal | 40 (41%) |
 Abnormal | 43 (44%) |
 Complex | 15 (15%) |
WHO classification | |
 With recurrent abnormalities | 44 (44%) |
 MDS-related | 10 (10%) |
 Post-therapy | 10 (10%) |
 Provisional entities | 12 (12%) |
 NOS | 19 (19%) |
 Myeloid sarcoma | 3 (3%) |
ELN risk | |
 Favorable | 25 (25.5%) |
 Intermediate | 55 (56.1%) |
 Adverse | 18 (18.4%) |
Treatment | |
 3 + 7 | 55 (56.1%) |
 Demethylating agents | 13 (13.3%) |
 LAM 1310 | 17 (17.3%) |
 Supportive therapies | 13 (13.3%) |
 AlloBMT | 22 (22%) |